Nanocarrier design for pathogen-inspired innate immune agonist delivery DOI Creative Commons
Griffin Kane, Meghan L. Brassil, Miranda Diaz-Infante

et al.

Trends in Immunology, Journal Year: 2024, Volume and Issue: 45(9), P. 678 - 692

Published: Aug. 26, 2024

In complex diseases such as cancer, modulating cytokine signatures of disease using innate immune agonists holds therapeutic promise. Novel multi-agonist treatments offer tunable control the system because they are uniquely pathogen inspired, eliciting robust antitumor responses by promoting synergistic responses. However, chief strategic hurdle is ensuring delivery to same target cells, highlighting importance nanomaterial-based carriers. Here, we place nanocarriers in center stage and review hurdles related varying extra- intracellular localizations receptors. We discuss a range nanomaterials used for delivery, their respective benefits drawbacks. Our overarching stance that rational nanocarrier design crucial developing pathogen-inspired immunotherapies.

Language: Английский

Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review DOI
Seyed Ali Aghapour, Mehdi Torabizadeh, Seyed Sobhan Bahreiny

et al.

Iranian Journal of Blood and Cancer, Journal Year: 2024, Volume and Issue: 16(2), P. 84 - 101

Published: June 1, 2024

Language: Английский

Citations

32
Nanoparticles Targeting Lymph Nodes for Cancer Immunotherapy: Strategies and Influencing Factors DOI
Zi‐Zhan Li, Nian‐Nian Zhong, Lei‐Ming Cao

et al.

Small, Journal Year: 2024, Volume and Issue: 20(19)

Published: Feb. 7, 2024

Abstract Immunotherapy has emerged as a potent strategy in cancer treatment, with many approved drugs and modalities the development stages. Despite its promise, immunotherapy is not without limitations, including side effects suboptimal efficacy. Using nanoparticles (NPs) delivery vehicles to target lymph nodes (LNs) can improve efficacy of reduce patients. In this context, paper reviews LN‐targeted immunotherapeutic NP strategies, mechanisms transport during LN targeting, their related biosafety risks. targeting LNs involves either passive influenced by physical properties, or active facilitated affinity ligands on surfaces, while alternative methods, such intranodal injection high endothelial venule (HEV) have uncertain clinical applicability require further research validation. NPs for increase biocompatibility, but risks toxicity, organ accumulation, oxidative stress remain, although strategies biodegradable biomacromolecules, polyethylene glycol (PEG) coating, impurity addition mitigate these Additionally, work concludes future‐oriented discussion, offering critical insights into field.

Language: Английский

Citations

22
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines DOI Creative Commons
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: March 5, 2025

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. integration novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, artificial intelligence have significantly expedited the development groundbreaking drugs, effectively addressing obstacles associated with their character, such as rapid clearance degradation, necessitating subcutaneous injection leading increasing patient discomfort, ultimately advancing translational research efforts. Peptides are presently employed in management diagnosis diverse array medical conditions, diabetes mellitus, weight loss, oncology, rare diseases, additionally garnering interest facilitating targeted platforms advancement vaccines. This paper provides an overview present market clinical trial progress therapeutics, platforms, It examines key areas through literature analysis emphasizes structural modification principles well recent advancements screening, design, technologies. accelerated including peptide-drug complexes, new vaccines, innovative diagnostic reagents, has potential promote era precise customization disease therapeutic schedule.

Language: Английский

Citations

2
Genetically Engineered Cytomembrane Nanovaccines for Cancer Immunotherapy DOI

Yuanwei Pan,

Xianjia Wu, Lujie Liu

et al.

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: 13(13)

Published: Feb. 7, 2024

Cancer nanovaccines have attracted widespread attention by inducing potent cytotoxic T cell responses to improve immune checkpoint blockade (ICB) therapy, while the lack of co-stimulatory molecules limits their clinical applications. Here, a genetically engineered cancer cytomembrane nanovaccine is reported that simultaneously overexpresses molecule CD40L and inhibitor PD1 elicit robust antitumor immunity for immunotherapy. The tumor antigens inherited from cytomembranes effectively stimulate dendritic (DC)-mediated activation cells, on significantly blocks PD1/PD-L1 signaling pathway, synergistically stimulating responses. Benefiting targeting ability cytomembranes, this formula shows an enhanced lymph node trafficking retention. Compared with original induces twofold DC maturation satisfactory precaution efficacy in breast mouse model. This offers simple, safe, strategy incorporating components

Language: Английский

Citations

7
Next generation CD40 agonists for cancer immunotherapy DOI Creative Commons
Hampus Andersson, Barnabas Nyesiga,

Tova Hermodsson

et al.

Expert Opinion on Biological Therapy, Journal Year: 2024, Volume and Issue: 24(5), P. 351 - 363

Published: May 3, 2024

Introduction There is a need for new therapies that can enhance response rates and broaden the number of cancer indications where immunotherapies provide clinical benefit. CD40 targeting an opportunity to meet this by promoting priming tumor-specific T cells reverting suppressive tumor microenvironment. This supported emerging evidence demonstrating benefits immunotherapy with antibodies in combination standard care chemotherapy.

Language: Английский

Citations

4
Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives DOI Creative Commons

Dekang Ren,

Shizheng Xiong, Yujie Ren

et al.

Computational and Structural Biotechnology Journal, Journal Year: 2024, Volume and Issue: 23, P. 1833 - 1843

Published: April 21, 2024

Preventive cancer vaccines are highly effective in preventing viral infection-induced cancer, but advances therapeutic with a focus on eliminating cells through immunotherapy limited. To develop vaccines, the integration of optimal adjuvants is potential strategy to enhance or complement existing approaches. However, conventional do not satisfy criteria clinical trials for vaccines. improve effects vaccination strategies must be formulated and novel identified. This review offers an overview current advancements highlights situ approaches that can synergistically combined other immunotherapies by harnessing adjuvant effects. Additionally, refinement systems using cutting-edge technologies elucidation molecular mechanisms underlying immunogenic cell death facilitate development innovative have been discussed. study lies providing crucial insights into applications designing more thereby facilitating application tumor promote death.

Language: Английский

Citations

3
Tumor Microenvironment Sequential Drug/Gene Delivery Nanosystem for Realizing Multistage Boosting of Cancer–Immunity Cycle on Cancer Immunotherapy DOI

Yongjing Cao,

Juan Li,

Qiangwei Liang

et al.

ACS Applied Materials & Interfaces, Journal Year: 2023, Volume and Issue: 15(47), P. 54898 - 54914

Published: Nov. 14, 2023

The antitumor immune response of cancer immunotherapy is a cascade cancer-immunity cycles (CIC). immunosuppression the tumor microenvironment and low immunogenicity cells, insufficient T lymphocyte activation, trafficking, infiltration caused failure to initiate run continuous multistage CIC, leading unsatisfactory outcomes. A doxorubicin/interleukin-12 plasmid DNA/celecoxib (DOX/pIL-12/CXB) combination strategy was designed by targeting CIC. Then, an intratumoral CXB-detachable nanosystem, or DOX/PAC/pIL-12 micelleplexes, developed for sequential drug/gene delivery facilitate boosting CIC on synergistic immunotherapy. micelleplexes could program intratumorally release CXB remodulate suppressing cyclooxygenase-2/prostaglandin E2 (COX-2/PGE2) pathway. smaller sizes surface charge-switched facilitated codelivery corelease DOX pIL-12 inside 4T1 cells. These exerted using activation amplification, providing therapeutic antimetastasis efficacy. nanosystem provides complete CIC-boosted combinatory developing against cancer.

Language: Английский

Citations

4
Nanocarrier design for pathogen-inspired innate immune agonist delivery DOI Creative Commons
Griffin Kane, Meghan L. Brassil, Miranda Diaz-Infante

et al.

Trends in Immunology, Journal Year: 2024, Volume and Issue: 45(9), P. 678 - 692

Published: Aug. 26, 2024

In complex diseases such as cancer, modulating cytokine signatures of disease using innate immune agonists holds therapeutic promise. Novel multi-agonist treatments offer tunable control the system because they are uniquely pathogen inspired, eliciting robust antitumor responses by promoting synergistic responses. However, chief strategic hurdle is ensuring delivery to same target cells, highlighting importance nanomaterial-based carriers. Here, we place nanocarriers in center stage and review hurdles related varying extra- intracellular localizations receptors. We discuss a range nanomaterials used for delivery, their respective benefits drawbacks. Our overarching stance that rational nanocarrier design crucial developing pathogen-inspired immunotherapies.

Language: Английский

Citations

0